Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed relapsed or refractory Non-Hodgkin lymphoma (NHL), according
to the World Health Organization (WHO)/Revised European-American Lymphoma
Classification, including any of the following subtypes:

- Mantle cell lymphoma

- Hairy cell leukemia

- Grade I, II, or III follicular lymphoma

- Marginal zone B-cell lymphoma

- Small lymphocytic lymphoma/B-cell chronic lymphocytic leukemia (SLL/CLL)

- Lymphoplasmacytic lymphoma (with or without Waldenstrom macroglobulinemia)

- History of transformed lymphoma and relapsed or refractory diffuse large B cell
lymphoma are included if patients are ineligible for or refuse hematopoietic stem
cell transplant

- Cutaneous B and T cell lymphoma are permitted. Cutaneous T cell lymphoma must be
refractory to 1 prior systemic therapy (topical therapy, photopheresis, and radiation
are not considered systemic therapy. Transformed B and T cell cutaneous lymphoma are
permitted.

- Relapsed or refractory nodal, leukemic, and extranodal T cell lymphomas are eligible.
Subtypes that are eligible include:

- Anaplastic large cell lymphoma

- Angioimmunoblastic T cell lymphoma

- PTCL-NOS

- Nasal or disseminated extranodal T/NK lymphoma

- Enteropathy-associated T cell lymphoma

- Hepatosplenic gamma/delta T cell lymphoma

- Subcutaneous panniculitis-like T cell lymphoma

- T-prolymphocytic leukemia

- Adult T-cell leukemia/lymphoma

- Large granular lymphocytic leukemia

- Aggressive NK leukemia

- Refractory to or relapsed after receiving ≥ 1 prior treatment regimen for lymphoma
(which may have included prior autologous stem cell transplantation) AND demonstrated
evidence of progressive disease by clinical and/or radiographic characteristics

- Measurable disease by radiographic criteria (≥ 2 cm by CT scan)

- Patients with leukemic forms of SLL/CLL must have an absolute lymphocytosis > 5
times 10^9/L with a B-cell phenotype and > 30% bone marrow lymphocytes

- No plasma cell myeloma or Hodgkin lymphoma

- No uncontrolled brain or leptomeningeal metastases, including ongoing requirement for
glucocorticoids for brain or leptomeningeal metastases

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless attributed to active
hemolysis or ineffective erythropoiesis)

- AST or ALT ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement by
lymphoma)

- ANC ≥ 1,500/μL

- WBC ≥ 3,000/μL

- Platelet count ≥ 100,000/μL

- Hemoglobin ≥ 9.0 g/dL

- Creatinine ≤ 1.5 times ULN

- Fasting cholesterol > 300 mg/dL (or > 7.75 mmol/L)

- Fasting triglycerides > 2.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Histologic confirmation of diagnosis, either are initial diagnosis or at any
subsequent relapse. Biopsy is not required at relapse, but is suggested

- No other malignancies within the past 3 years, except for adequately treated
carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, or
curatively treated low-risk prostate cancer

- No severe and/or uncontrolled medical condition that would preclude study
participation, including the following:

- Unstable angina pectoris

- New York Heart Association class III or IV symptomatic congestive heart failure

- Myocardial infarction within the past 6 months

- Serious uncontrolled cardiac arrhythmia

- Severely impaired lung function

- Any active (acute or chronic) or uncontrolled infection and/or disorder

- Liver disease (e.g., viral hepatitis B or C, cirrhosis, chronic active
hepatitis, or chronic persistent hepatitis)

- Known history of HIV seropositivity

- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of everolimus (e.g., ulcerative disease,
uncontrolled nausea, vomiting, or diarrhea, or malabsorption syndrome)

- Non-malignant medical illness that is uncontrolled or whose control may be
jeopardized by study therapy

- None of the following diabetic conditions:

- Diabetes mellitus currently requiring insulin therapy

- Preexisting poorly controlled diabetes mellitus (e.g., hemoglobin A1c value > 9%
within the past 4 weeks)

- Uncontrolled diabetes, defined by fasting serum glucose > 1.5 times ULN (off
medications)

- No preexisting peripheral neuropathy ≥ grade 2

- No active bleeding diathesis

- No known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus,
temsirolimus) or to its excipients, or to bortezomib, boron, or mannitol

- No history of noncompliance to medical regimens

- No personal, medical, or psychiatric reason that would preclude compliance with study
requirements

PRIOR CONCURRENT THERAPY:

- More than 4 weeks since prior chemotherapy or investigational drug

- More than 3 months since prior monoclonal antibody

- More than 1 week since prior and no concurrent strong P450/CY3PA4 inhibitors

- No prior allogeneic stem cell transplantation

- No prior small bowel resection that may significantly alter the absorption of
everolimus

- No concurrent immunization with attenuated live vaccine

- No concurrent chronic treatment with systemic steroids or other immunosuppressive
agents

- No other concurrent investigational or anticancer agents